BRAZILIAN CONSENSUS STATEMENT ON VISCOSUPPLEMENTATION OF THE KNEE (COBRAVI)
Authors:
- Gustavo Constantino de CamposGCGustavo Constantino de Campos
- Eduardo Branco de SousaESEduardo Branco de Sousa
- Paulo César HamdanPHPaulo César Hamdan
- Cyro Scala de Almeida JúniorCJCyro Scala de Almeida Júnior
- Antonio Martins TieppoATAntonio Martins Tieppo
- Marcia Uchôa de RezendeMRMarcia Uchôa de Rezende
- Adrieni Antunes Do Amaral AlchaarAAAdrieni Antunes Do Amaral Alchaar
- Carlos Bruno PinheiroCPCarlos Bruno Pinheiro
- Eduardo de Melo Carvalho RochaEREduardo de Melo Carvalho Rocha
- Fabiano Gonçalves CunhaFCFabiano Gonçalves Cunha
- Ivan PachecoIPIvan Pacheco
- Mário Sérgio Rossi VieiraMVMário Sérgio Rossi Vieira
Open Access
- 1 August 2019
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Acta Ortopedica Brasileira
- Vol. 27 (4) , 230-236
Abstract
Objective: The aim of this consensus statement on viscosupplementation is to serve as a reference document based on relevant literature and clinical experience in the treatment of knee osteoarthritis using an intra-articular injection of hyaluronic acid, covering key aspects such as clinical indications, effectiveness, and tolerability. Methods: A multidisciplinary panel including two sports medicine physicians, six orthopedists, four physiatrists, and two rheumatologists were selected based on their clinical and academic experience of viscosupplementation. Sixteen statements were prepared and discussed, after which a vote was held. Each member of the panel gave a score between 0 and 10 on a Likert scale, specifying their level of agreement with the statement. Results: The panel reached a consensus on several issues. Specifically, the panel agreed that the best indication is for mild to moderate knee arthrosis; prior or concomitant use of intraarticular triamcinolone hexacetonide may optimize the effect of hyaluronic acid; viscosupplementation should not be performed as an isolated procedure but in conjunction with other rehabilitative and pharmacological measures; viscosupplementation has analgesic, anti-inflammatory, and chondroprotective effects; and viscosupplementation is cost-effective. Conclusion: This consensus statement provides clear information and guidance for both individuals and payers. Level of evidence V, Consensus statement.Keywords
This publication has 64 references indexed in Scilit:
- Where and how to inject the knee—A systematic reviewSeminars in Arthritis and Rheumatism, 2013
- Ensaio clínico prospectivo e randomizado: regime único e semanal de viscossuplementaçãoActa Ortopedica Brasileira, 2013
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA projectAnnals of the Rheumatic Diseases, 2011
- Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trialBMC Musculoskeletal Disorders, 2011
- Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysisOsteoarthritis and Cartilage, 2011
- Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trialAnnals of the Rheumatic Diseases, 2010
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500–730 kDa sodium hyaluronate (Hyalgan®) and methylprednisolone acetate on primary osteoarthritis of the kneeOsteoarthritis and Cartilage, 2001